Delanzomib clinical trials
Also written CEP-18770.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses delanzomib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2007 (1)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2010 | 1 |
| 2011 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Teva Branded Pharmaceutical Products R&D, Inc. (1) · Ethical Oncology Science (1) · Cephalon (1)
Related medicines
As reviewed, each with the page that says it.
- One of Proteasome inhibitors source
Studies
Open first, then newest update. How each study uses delanzomib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple MyelomaCompletedPhase 1/2Teva Branded Pharmaceutical Products R&D, Inc.NCT01348919Written as CEP-18770
- Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent TherapyTerminatedPhase 1/2CephalonNCT01023880Written as CEP-18770
- Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's LymphomasCompletedPhase 1Ethical Oncology ScienceNCT00572637Written as CEP-18770
Codes
What other systems call delanzomib · ClinicalTrials.gg INT005253
- MeSH (NLM) C527966delanzomibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 6IF28942WODELANZOMIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27264956delanzomibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C74075DelanzomibOne source FDA
- DrugBank DB11956One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C527966 | delanzomib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 6IF28942WO | DELANZOMIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27264956 | delanzomib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C74075 | Delanzomib | One source FDA |
| DrugBank | DB11956 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.